Investigational drug · Phase 3
pudexacianinium chloride
Also called: ASP5354
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Intraoperative Ureter Visualization, Abdominolpelvic Surgery.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
6
Any phase or sponsor naming "pudexacianinium chloride"
First trial start
2023
Aug 2, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "pudexacianinium chloride", any sponsor or status.
Conditions studied
As listed on its trial records.
- Intraoperative Ureter Visualization
- Abdominolpelvic Surgery
Largest trials
Live from ClinicalTrials.gov: studies naming "pudexacianinium chloride" as an intervention, largest first.
- A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During SurgeryPivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05754333 · 107 participants · Start Aug 2, 2023 · Primary completion Dec 17, 2024
Drug: pudexacianinium chloride · For: Intraoperative Ureter Visualization; Abdominolpelvic Surgery
Sites: Orlando, Florida; Tampa, Florida; Weston, Florida · 6 sites in all
- A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney DiseasePivotal-lookingCompleted
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05999747 · 95 participants · Start Mar 19, 2024 · Primary completion Oct 13, 2025
Drug: pudexacianinium chloride · For: Intraoperative Ureter Visualization; Abdominolpelvic Surgery
Sites: Los Angeles, California; Newport Beach, California; Tampa, Florida · 12 sites in all
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT05495581 · 28 participants · Start Aug 25, 2022 · Primary completion Apr 27, 2023
Drug: pudexacianinium chloride · For: Healthy Volunteers; Renal Impairment
Sites: Anniston, Alabama; Tustin, California; Miami, Florida · 4 sites in all
Astellas Pharma IncAstellas (ALPMY)
NCT04238481 · 13 participants · Start Oct 6, 2020 · Primary completion Nov 18, 2021
Drug: Pudexacianinium chloride · For: Laparoscopic/Minimally Invasive Colorectal Surgery
Sites: Orlando, Florida; New Orleans, Louisiana
Astellas Pharma IncAstellas (ALPMY)
NCT04878471 · 12 participants · Start Jun 2, 2021 · Primary completion Jul 22, 2021
Drug: Pudexacianinium chloride; Placebo · For: Healthy Volunteers
Sites: Sumida-ku, Japan
Astellas Pharma IncAstellas (ALPMY)
NCT05457842 · 1 participants · Start Aug 10, 2022 · Primary completion Sep 2, 2022
Drug: pudexacianinium chloride · For: Sentinel Lymph Node Biopsy; Breast Cancer; Melanoma
Sites: Orange, California
Newest research
PubMed records naming it or its code names, newest first.
- Pudexacianinium chloride (ASP5354) for ureter visualization in patients undergoing abdominopelvic surgery: a phase III, multicenter, open-label, randomized study.
Albert M, Lautz TB, Allawi A, et al. · Surg Endosc 2026
- Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration.
Kojima T, Saito M, Matsuda T, et al. · Eur J Clin Pharmacol 2026
- Reliability of Likert Scale for Surgeon-Rated Conspicuity of Ureters with Pudexacianinium Chloride (ASP5354).
Atzinger C, Dickerson H, Polek E, et al. · JSLS 2025
- [Development of Intraoperative Near-infrared Fluorescent Ureteral Imaging Agent to Prevent Iatrogenic Ureteral Injury].
Teranishi K · Yakugaku Zasshi 2025
- Population Pharmacokinetic Modeling and Simulation of Pudexacianinium (ASP5354) for Dose Setting of a Phase 2 First-in-Patient Study: A Novel Imaging Agent for Intraoperative Ureter Visualization during Abdominopelvic Surgery.
Saito M, Kojima T, Komatsu K, et al. · Clin Pharmacol Drug Dev 2024
- Pudexacianinium (ASP5354) chloride for ureter visualization in participants undergoing laparoscopic, minimally invasive colorectal surgery.
Albert M, Delgado-Herrera L, Paruch J, et al. · Surg Endosc 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.